See what’s new.
Extellis raises $6.8 M seed round to unlock reliable satellite imagery at an industrial scale
Oversubscribed round, led by Oval Park Capital, funds first orbital demonstration and initial product rollout.
Vega Health Launches to Deliver on AI’s Promise in Healthcare
Backed by Bessemer Venture Partners, Vega Health raises $4 million to connect health systems with AI solutions through curated marketplace, proprietary integration platform, and objective monitoring to maximize value
Duke Startup Resolv to Deliver Valuable Building and Construction Insights
Resolv, a spinout of Duke University’s Pratt School of Engineering, closed on $5 million seed funding round to develop metamaterials-based device that could impact the $10 billion building construction and remediation industry.
Duke Inventions Return a Record $115M Revenue in FY25, Highlighting Momentum in Research Translation
OTC reports highest-ever revenue as invention disclosures rise, while Duke Capital Partners delivers its strongest investment year ever.
The Translational Matchmakers: How Technology Marketing Connects Inventors with Industry
At OTC, the Technology Marketing team plays a pivotal role in moving discoveries beyond the lab.
Hands-on workshop shows Triangle’s academic life science innovators how to build their startup in FDA regulated markets
Academics from around the Triangle brought their cutting-edge biomedical innovations to a three-day startup workshop hosted by Duke, NC State, and UNC.
restor3d Secures $38 Million in Growth Capital to Drive Expansion and Innovation in Personalized Orthopedic Solutions
Newly raised funds will allow the Duke spinout to scale its personalized orthopedic solutions, advancing 3D printing and AI technologies for improved surgical outcomes.
Uplinza® (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Originally developed at Duke, Amgen’s UPLIZNA® secures FDA approval as the first treatment for IgG4-related disease, achieving an 87% reduction in flare risk through CD19+ B-cell targeting.
Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag™ AAV Reagent
Isolere Bio by Donaldson, a Duke spinout, announces the launch of its manufacturing-grade IsoTag™ AAV reagent, marking a major milestone in advancing gene therapy manufacturing technologies.